Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

NCT: NCT04567303 · ACTIVE_NOT_RECRUITING

NCT IDNCT04567303
StatusACTIVE_NOT_RECRUITING
Start Date2020-10-28
Completion2026-08-01

Brief Summary

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).

Frequently Asked Questions

What is Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration?

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration is a clinical trial registered under NCT04567303. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04567303?

The current status of NCT04567303 (Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration) is: ACTIVE_NOT_RECRUITING.

When did Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration start?

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration started on 2020-10-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑